To ask Her Majesty’s Government what processes have been put in place to ensure equitable access to molecular diagnostics across the National Health Service for medicines listed on the Cancer Drugs Fund.

NHS England has advised that it is not the sole commissioner of molecular diagnostic testing.

Work is currently underway to clarify legacy arrangements for how such tests are currently commissioned and ensure alignment with the National Tariff payment rules. It is NHS England’s intention to ensure that a whole systems approach to the future commissioning of diagnostics within specialised services and by clinical commissioning groups forms part of a clinical and scientific strategy informing new models of care and the implementation of the Five Year Forward View.